Sunshine Biopharma (SBFM) Free Cash Flow (2010 - 2026)

Sunshine Biopharma has reported Free Cash Flow for 17 years, with the latest figure at -$2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 22.01% year-over-year to -$2.1 million; the trailing twelve-month figure through Mar 2026 stood at -$5.9 million (up 53.46% YoY), and the FY2025 full-year result was -$5.5 million, up 61.18% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$2.1 million, down from -$1.6 million in the prior quarter.
• The five-year high for Free Cash Flow was -$466923.0 in Q3 2023, with the low at -$5.6 million in Q2 2024.
• Historically, Free Cash Flow has averaged -$2.1 million across 5 years, with a median of -$1.9 million in 2023.
• Annual changes were most pronounced in 2022 — Free Cash Flow slumped 681.96% — and 2025, when it jumped 73.84%.
• Sunshine Biopharma's Free Cash Flow stood at -$2.4 million in 2022, then gained by 5.46% to -$2.3 million in 2023, then tumbled by 52.03% to -$3.5 million in 2024, then jumped by 53.96% to -$1.6 million in 2025, then dropped by 28.62% to -$2.1 million in 2026.
• The last three Free Cash Flow figures came in at -$2.1 million (Q1 2026), -$1.6 million (Q4 2025), and -$735840.0 (Q3 2025), per Business Quant data.